PTCT - PTC Therapeutics Price-to-Projected Revenue Ratio

PTC Therapeutics, Inc. (PTCT) management demonstrates high expertise in developing orphan drugs, although the commercial division requires stabilization. The company's forward P/S on this chart visualizes the link between market capitalization and expected revenue, where 4.60 reflects the latest value of the metric. The strategy is based on gene therapy and RNA splicing, while global drug delivery relies on flawless specialized protocols.

PTC Therapeutics Inc - PTCT Projected Price to Revenue (period 07/04/2022 - 11/15/2026)

Financial and market metric breakdowns for PTC Therapeutics (PTCT)

- market price and analyst price targets:

Price Chart PTC Therapeutics Corp|PTCT - Price Target Chart

- market capitalization statistics:

Market Value PTC Bio|PTCT - Total Enterprise Value

- book value of equity indicators:

Book Value per Share PTC Therapeutics|PTCT - Book Value of Business|Market Cap to Net Assets Ratio ptcbio.com|PTCT - Company Assets

- debt and liquidity data:

Debt to Equity PTC Therapeutics, Inc.|PTCT - Long-Term Liabilities to Equity|Short-Term Debt to Equity Ratio PTC Therapeutics, Inc.|PTCT - Company Cumulative Indebtedness|Debts to Book Capitalization PTC Therapeutics Inc|PTCT - Company Long-Term Liabilities|Company Current Liabilities PTC Therapeutics|Quick Liquidity Indicator ptcbio.com

- financial results and valuation multiples details:

PTCT - Profit After Payment of Taxes|Projected Future Earnings PTC Therapeutics, Inc.|PTCT - Company Value to Net Income|Forward P/E Multiple PTC Therapeutics Inc|PTCT - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PTC Therapeutics Inc|PTCT - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) PTC Therapeutics|PTCT - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months ptcbio.com|PTCT - Earnings per share trend in current year|Earnings growth forecast for next year PTC Therapeutics, Inc.

- revenue and sales proceeds data:

PTCT - Company Total Revenue|Company Future Sales Volume PTC Therapeutics Inc|PTCT - P/S Multiple|Forward Price-to-Revenue Multiple PTC Bio|PTCT - Revenue Change YoY (Last 12 Months)

General company analysis:PTC Bio PTCT

For PTC Therapeutics, Inc. (PTCT), which is transitioning toward the commercialization of gene therapy, the forward P/S ratio serves as a gauge of market expectations regarding sales scaling. This multiple relates current market capitalization to projected revenue, allowing for the valuation of each unit of future income without waiting for financial reports. The price action of the forward P/S indicator reflects phases of investor optimism, determining the balance between business growth strength and the asset's potential return.

Competitors of PTC Therapeutics, Inc. (PTCT)

Price-to-Projected Revenue Ratio Jazz Pharma JAZZ|Cytokinetics Corp - Price-to-Projected Revenue Ratio|SRRK - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Centessa Pharmaceuticals|DYN (Dyne Corp) - Forward Price-to-Revenue Multiple|Projected Price to Revenue Edgewise Pharma EWTX|Forward Price-to-Revenue Multiple RAPP|Market Cap to Future Revenue Ratio Alumis Corp ALMS|Forward Price-to-Revenue Multiple ZVRA (Kempharm)|Forward Price-to-Revenue Multiple contineum-tx.com CTNM|Forward P/S Multiple LRMR (larimartx.com)|Forward P/S Multiple Capricor Therapeutics CAPR|TRDA: Forward Price-to-Revenue Multiple|PTHS - Forward P/S Multiple|MNOV: Forward P/S Multiple|Market Cap to Projected Revenue SER|BTAI (BioXcel Therapeutics Inc) - Forward P/S Multiple|ProMIS Neurosciences, Inc. (PMN) - Market Cap to Expected Sales Ratio|Forward P/S Multiple APUS|Price-to-Projected Revenue Ratio AEON (AEON Biopharma, Inc.)|Forward P/S Multiple NLSP (NLS Pharmaceutics Ltd.)|Market Cap to Expected Sales Ratio Bionomics Ltd (BNOX)|HUGE - Price-to-Projected Revenue Ratio|Forward Price to Sales RETA (Reata Pharmaceuticals, Inc.)